º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Sunderland medical cannabis firm expands and swaps minimum wage for starting salaries

Curaleaf Laboratories is eyeing up future growth in the º£½ÇÊÓÆµ market

Sunderland's Curaleaf Laboratories imports cannabis grown in Spain and Portugal to make prescription products for the º£½ÇÊÓÆµ market.(Image: Curaleaf Laboratories)

A Sunderland firm that claims to be among the first in the º£½ÇÊÓÆµ to produce medical cannabis is expanding into new headquarters and boosting the pay of some staff.

Curaleaf Laboratories is set to move into new premises on Wessington Way and introduce a £25,000 minimum starting salary for those workers previously earning minimum wage. The 187-strong business, which was born out of pharmaceutical 'specials' maker Rokshaw Laboratories, says it hopes the move will encourage similar sized companies to follow suit.

The £19m turnover firm became part of US-based Curaleaf's European business in 2019, joining its strategy to bring medical cannabis to a wider market. Owing to º£½ÇÊÓÆµ laws, the firm's plants are grown to exacting standings in Spain and Portugal before the raw material is shipped to Wearside for processing into a range of products which can be prescribed by Curaleaf's own network of clinicians.

Read more: Newcastle biotech company InvenireX secures £500,000 investment

Read more: Metrocentre sees increase in footfall, revenue and occupancy rates

Since its inception 11 years ago by brothers Jonathan and Richard Hodgson, Rokshaw had created bespoke, alternative forms of medicines. The firm became focused on medical cannabis, which is a multibillion-dollar industry in the US but has only slowly taken shape in the º£½ÇÊÓÆµ following changes in the law over the past six years.

Following the firm's acquisition by Curaleaf, it has focussed efforts on creating a series of products such as gummies, vape cartridges and dried cannabis bud. At the moment patients are unable to get it prescribed on the NHS, other than in a small number of specialist cases, so the firm operates a virtual private clinic where people, typically sufferers of chronic pain, can get an online consultation with consultants, doctors and pharmacists.

The Sunderland firm has identified growth in the market with suggests that about 1-2% of the population could be using medical cannabis products within five years. Meanwhile Curaleaf International is targeting growth around Europe where laws are being changed in some countries.